BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Mr. Jeong Woo Choo has been appointed as the President and CEO of SK Biopharmaceuticals and SK Life Science

December 1, 2017 | News

During his career in the pharmaceutical industry, Dr. Kamin has designed and managed trials in many areas of neuroscience including migraine, eating disorders, bipolar disorder, alcohol addiction, acute and chronic pain, peripheral neuropathy, amyotrophic lateral sclerosis, fibromyalgia and epilepsy.



Jeong Woo Cho, Ph.D., has been appointed president and CEO of SK biopharmaceuticals and SK life science to lead the company through the next phase of its evolution.

Dr. Cho began his career at SK in 2001, becoming chief operating officer and executive vice president, leading the enterprise's drug development business. In that role, he was responsible for managing all activities associated with the clinical development programs for key CNS assets and managed global project teams in the U.S., EU, and Asia.

"I'm excited to be leading SK life science as we build and expand the company's presence in the United States and advance our promising pipeline," Dr. Cho said. "With numerous compounds in clinical development, we are taking on the mysteries of the brain in our pursuit of life-changing solutions for people affected by CNS disorders."

Marc Kamin, M.D., is SK life science's chief medical officer and Sebby Borriello is vice president and chief commercial officer.

During his career in the pharmaceutical industry, Dr. Kamin has designed and managed trials in many areas of neuroscience including migraine, eating disorders, bipolar disorder, alcohol addiction, acute and chronic pain, peripheral neuropathy,

amyotrophic lateral sclerosis, fibromyalgia and epilepsy. Notably, Dr. Kamin's epilepsy experience includes a role in the successful launch of Johnson & Johnson's blockbuster anti-epileptic drug TOPAMAX. Throughout his career, he has been involved in the strategic aspects of drug development, as well as medical marketing activities.

"For the patients, physicians, advocates, and scientists, SK life science is here listening to your needs, developing new molecules, enhancing advocacy efforts, and providing solutions that change what's possible in CNS treatment," said Dr. Kamin.

Borriello joined SK life science from Cempra Pharmaceuticals, where he served as vice president of market development and was responsible for all pre-commercial efforts, including key opinion leader (KOL) development and commercial advisory boards. Prior to his time at Cempra, he worked for more than 26 years at Johnson & Johnson. Like Dr. Kamin, Borriello played a key role in the successful launch of TOPAMAX®.

"Nothing is more powerful than when individuals with unique experiences and ideas come together with a common goal, and that's the kind of team that we're excited to build," said Borriello. "With an existing legacy in drug development and out-licensing, our team at SK life science is now poised to move on to the next phase of our corporate journey, commercializing meaningful products here in the U.S. market."